Clinical Trials Directory

Trials / Conditions / Recurrent Glioblastoma, IDH-Wildtype

Recurrent Glioblastoma, IDH-Wildtype

11 registered clinical trials studyying Recurrent Glioblastoma, IDH-Wildtype — 7 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingComparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
NCT07349693
Everfront Biotech Co., Ltd.Phase 2 / Phase 3
Not Yet RecruitingTesting the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patie
NCT07422363
National Cancer Institute (NCI)Phase 1
RecruitingGI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Gliob
NCT07301268
Mayo ClinicPhase 2
RecruitingA Clinical Trial of P134 Cells in Recurrent Glioblastoma
NCT07318818
Tasly Pharmaceutical Group Co., LtdPhase 1 / Phase 2
SuspendedTesting the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblasto
NCT06860594
National Cancer Institute (NCI)Phase 1
WithdrawnTesting the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients Wit
NCT06328036
National Cancer Institute (NCI)Phase 2
RecruitingD2C7-IT + 2141-V11 Combination Post-resection in rGBM
NCT06455605
Darell BignerPhase 1
Active Not RecruitingTriapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
NCT06410248
Northwestern UniversityPhase 1
RecruitingAllogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astr
NCT05789394
Mayo ClinicPhase 1
SuspendedTesting the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for
NCT05432804
National Cancer Institute (NCI)Phase 1 / Phase 2
RecruitingEfineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
NCT05465954
Mayo ClinicPhase 2